TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52 Week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg Once-daily Alone and in Combination With GW642444 25mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Subjects With Chronic Obstructive Pulmonary Disease
Brief Summary: The purpose of this 52-week study is to evaluate the long-term safety (in terms of adverse events, COPD exacerbations, laboratory, ECG, and Holter findings, vital signs, use of rescue medication and lung function) of GSK573719/GW642444 Inhalation Powder 125/25mcg in subjects with COPD. The long-term safety of GSK573719 Inhalation Powder 125mcg will also be evaluated. A placebo arm is included to evaluate these products compared to an inactive control.


Options:
A: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Budesonide/formoterol (Symbicort Turbuhaler) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol (Oxis Turbuhaler) | Intervention Type: DRUG; Name: Budesonide/formoterol (Symbicort Turbuhaler); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol (Oxis Turbuhaler); Assigned to Arm(s): 2
C: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: 125/25 mcg once-daily GSK573719/GW642444 | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: 125mcg once-daily GSK573719 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo once-daily | Intervention Type: DRUG; Name: 125/25 mcg once-daily GSK573719/GW642444; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: 125mcg once-daily GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: Placebo once-daily; Assigned to Arm(s): Placebo
D: Arm Label: QVA149 + placebo to tiotropium; Type: EXPERIMENTAL; Interventions: Drug: QVA149, Drug: Placebo to tiotropium, Drug: Salbutamol/albuterol | Arm Label: Tiotropium + placebo to QVA149; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Placebo to QVA149, Drug: Salbutamol/albuterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to QVA149, Drug: Placebo to tiotropium, Drug: Salbutamol/albuterol | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 + placebo to tiotropium | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium + placebo to QVA149 | Intervention Type: DRUG; Name: Placebo to QVA149; Assigned to Arm(s): Placebo, Tiotropium + placebo to QVA149 | Intervention Type: DRUG; Name: Placebo to tiotropium; Assigned to Arm(s): Placebo, QVA149 + placebo to tiotropium | Intervention Type: DRUG; Name: Salbutamol/albuterol; Assigned to Arm(s): Placebo, QVA149 + placebo to tiotropium, Tiotropium + placebo to QVA149

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52 Week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg Once-daily Alone and in Combination With GW642444 25mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Subjects With Chronic Obstructive Pulmonary Disease
Brief Summary: The purpose of this 52-week study is to evaluate the long-term safety (in terms of adverse events, COPD exacerbations, laboratory, ECG, and Holter findings, vital signs, use of rescue medication and lung function) of GSK573719/GW642444 Inhalation Powder 125/25mcg in subjects with COPD. The long-term safety of GSK573719 Inhalation Powder 125mcg will also be evaluated. A placebo arm is included to evaluate these products compared to an inactive control.


Options:
A: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: QAB149; Type: ACTIVE_COMPARATOR; Interventions: Drug: QAB149 | Arm Label: NVA237; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: QAB149; Assigned to Arm(s): QAB149 | Intervention Type: DRUG; Name: NVA237; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: 125/25 mcg once-daily GSK573719/GW642444 | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: 125mcg once-daily GSK573719 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo once-daily | Intervention Type: DRUG; Name: 125/25 mcg once-daily GSK573719/GW642444; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: 125mcg once-daily GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: Placebo once-daily; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol plus Placebo (Tiotropium) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Formoterol plus Tiotropium | Intervention Type: DRUG; Name: Formoterol plus Placebo (Tiotropium); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol plus Tiotropium; Assigned to Arm(s): 2
D: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: 62.5/25mcg | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: 62.5mcg | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: 25mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 62.5/25mcg; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: 62.5mcg; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: 25mcg; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52 Week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg Once-daily Alone and in Combination With GW642444 25mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Subjects With Chronic Obstructive Pulmonary Disease
Brief Summary: The purpose of this 52-week study is to evaluate the long-term safety (in terms of adverse events, COPD exacerbations, laboratory, ECG, and Holter findings, vital signs, use of rescue medication and lung function) of GSK573719/GW642444 Inhalation Powder 125/25mcg in subjects with COPD. The long-term safety of GSK573719 Inhalation Powder 125mcg will also be evaluated. A placebo arm is included to evaluate these products compared to an inactive control.


Options:
A: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: 125/25 mcg once-daily GSK573719/GW642444 | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: 125mcg once-daily GSK573719 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo once-daily | Intervention Type: DRUG; Name: 125/25 mcg once-daily GSK573719/GW642444; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: 125mcg once-daily GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: Placebo once-daily; Assigned to Arm(s): Placebo
B: Arm Label: Umeclidinium 62.5 mcg + placebo; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium, Drug: Umeclidinium matching placebo | Arm Label: Tiotropium 18mcg + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Tiotropium matching placebo | Intervention Type: DRUG; Name: Umeclidinium; Assigned to Arm(s): Umeclidinium 62.5 mcg + placebo | Intervention Type: DRUG; Name: Umeclidinium matching placebo; Assigned to Arm(s): Umeclidinium 62.5 mcg + placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium 18mcg + placebo | Intervention Type: DRUG; Name: Tiotropium matching placebo; Assigned to Arm(s): Tiotropium 18mcg + placebo
C: Arm Label: Umeclidinium/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/Vilanterol 62.5/25 mcg | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 mcg | Intervention Type: DRUG; Name: Umeclidinium/Vilanterol 62.5/25 mcg; Assigned to Arm(s): Umeclidinium/Vilanterol | Intervention Type: DRUG; Name: Tiotropium 18 mcg; Assigned to Arm(s): Tiotropium
D: Arm Label: Umeclidinium 62.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium | Arm Label: Glycopyrronium 44 mcg; Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium | Intervention Type: DRUG; Name: Umeclidinium; Assigned to Arm(s): Umeclidinium 62.5 mcg | Intervention Type: DRUG; Name: Glycopyrronium; Assigned to Arm(s): Glycopyrronium 44 mcg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CONFUCIUS Study : Impact of a Multifaceted Program to Prevent Postoperative Delirium in the Elderly
Brief Summary: Postoperative delirium is common in the elderly and is associated with a significant increase in mortality, complications, length of hospital stay and admission in long care facility. Several interventions have proved their effectiveness to prevent it but their combination within a multifaceted intervention needs to be assessed using rigorous methodology based on randomized study design. CONFUCIUS trial aims to measure the impact of a multifaceted program on the prevention of postoperative delirium in elderly.


Options:
A: Arm Label: multifaceted prevention program; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted prevention program HELP(Hospital Elder Life Program) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted prevention program HELP(Hospital Elder Life Program); Assigned to Arm(s): multifaceted prevention program
B: Arm Label: Combined Epi-GA/PCEA; Type: EXPERIMENTAL; Interventions: Procedure: Combined Epi-GA/PCEA | Arm Label: GA/PCIA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: GA/PCIA | Intervention Type: PROCEDURE; Name: Combined Epi-GA/PCEA; Assigned to Arm(s): Combined Epi-GA/PCEA | Intervention Type: PROCEDURE; Name: GA/PCIA; Assigned to Arm(s): GA/PCIA
C: Arm Label: Deeper sedation; Type: ACTIVE_COMPARATOR; Interventions: Device: Deeper sedation | Arm Label: Moderate sedation; Type: ACTIVE_COMPARATOR; Interventions: Device: Moderate sedation | Intervention Type: DEVICE; Name: Deeper sedation; Assigned to Arm(s): Deeper sedation | Intervention Type: DEVICE; Name: Moderate sedation; Assigned to Arm(s): Moderate sedation
D: Intervention Type: PROCEDURE; Name: Orthogeriatric intervention; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CONFUCIUS Study : Impact of a Multifaceted Program to Prevent Postoperative Delirium in the Elderly
Brief Summary: Postoperative delirium is common in the elderly and is associated with a significant increase in mortality, complications, length of hospital stay and admission in long care facility. Several interventions have proved their effectiveness to prevent it but their combination within a multifaceted intervention needs to be assessed using rigorous methodology based on randomized study design. CONFUCIUS trial aims to measure the impact of a multifaceted program on the prevention of postoperative delirium in elderly.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Group-based exercise training during hospitalization | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Group-based exercise training during hospitalization; Assigned to Arm(s): Intervention
B: Intervention Type: PROCEDURE; Name: Orthogeriatric intervention; Assigned to Arm(s): N/A
C: Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Behavioral: a modified NTU-HELP | Intervention Type: BEHAVIORAL; Name: a modified NTU-HELP; Assigned to Arm(s): Experimental Group
D: Arm Label: multifaceted prevention program; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted prevention program HELP(Hospital Elder Life Program) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted prevention program HELP(Hospital Elder Life Program); Assigned to Arm(s): multifaceted prevention program

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CONFUCIUS Study : Impact of a Multifaceted Program to Prevent Postoperative Delirium in the Elderly
Brief Summary: Postoperative delirium is common in the elderly and is associated with a significant increase in mortality, complications, length of hospital stay and admission in long care facility. Several interventions have proved their effectiveness to prevent it but their combination within a multifaceted intervention needs to be assessed using rigorous methodology based on randomized study design. CONFUCIUS trial aims to measure the impact of a multifaceted program on the prevention of postoperative delirium in elderly.


Options:
A: Arm Label: Liberal (10 g/dL) Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Liberal (10 g/dL) Transfusion Strategy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Restrictive (Symptomatic) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Liberal (10 g/dL) Transfusion Strategy; Assigned to Arm(s): Liberal (10 g/dL) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Restrictive (Symptomatic) Transfusion Strategy; Assigned to Arm(s): 2
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Multicomponent nurse-led intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Multicomponent nurse-led intervention; Assigned to Arm(s): Intervention Group
C: Arm Label: multifaceted prevention program; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted prevention program HELP(Hospital Elder Life Program) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted prevention program HELP(Hospital Elder Life Program); Assigned to Arm(s): multifaceted prevention program
D: Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Behavioral: a modified NTU-HELP | Intervention Type: BEHAVIORAL; Name: a modified NTU-HELP; Assigned to Arm(s): Experimental Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The primary objective is to test the hypothesis that the use of the Pressure Right device in combination with ondansetron and dexamethasone would result in a lower incidence of postoperative vomiting (emesis) than the combination of antiemetic therapy alone.


Options:
A: Arm Label: P6 acupressure group; Type: ACTIVE_COMPARATOR; Interventions: Device: P6 acupressure band | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo band | Intervention Type: DEVICE; Name: P6 acupressure band; Assigned to Arm(s): P6 acupressure group | Intervention Type: OTHER; Name: Placebo band; Assigned to Arm(s): Placebo group
B: Arm Label: Acustimulation; Type: EXPERIMENTAL; Interventions: Device: Acustimulation | Arm Label: Standard treatment group; Type: NO_INTERVENTION; Interventions: Device: Acustimulation | Intervention Type: DEVICE; Name: Acustimulation; Assigned to Arm(s): Acustimulation, Standard treatment group
C: Intervention Type: DEVICE; Name: Acupressure; Assigned to Arm(s): N/A
D: Intervention Type: DEVICE; Name: Vital-band (R); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Folic Acid and B Vitamins for Secondary Prevention of Stroke : A Double-blinded Randomized Controlled Trial
Brief Summary: The CSSPT study is a multi-center, randomized, double blinded, placebo-controlled secondary stroke prevention trial in China to determine whether the addition of folic acid and vitamin supplements will reduce recurrent stroke events and other combined incidence of recurrent vascular events and vascular death.


Options:
A: Arm Label: vitamin supplements; Type: EXPERIMENTAL; Interventions: Drug: Folic Acid, Drug: Vitamin B6, Drug: Vitamin B12 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: Vitamin B6; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: Vitamin B12; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BEHAVIORAL; Name: folic acid (0.8 mg); Assigned to Arm(s): N/A
C: Arm Label: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo | Arm Label: Placebo Tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo; Assigned to Arm(s): Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Tablet
D: Arm Label: Vitamin B12; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin B12 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12; Assigned to Arm(s): Vitamin B12 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Folic Acid and B Vitamins for Secondary Prevention of Stroke : A Double-blinded Randomized Controlled Trial
Brief Summary: The CSSPT study is a multi-center, randomized, double blinded, placebo-controlled secondary stroke prevention trial in China to determine whether the addition of folic acid and vitamin supplements will reduce recurrent stroke events and other combined incidence of recurrent vascular events and vascular death.


Options:
A: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
B: Arm Label: vitamin supplements; Type: EXPERIMENTAL; Interventions: Drug: Folic Acid, Drug: Vitamin B6, Drug: Vitamin B12 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: Vitamin B6; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: Vitamin B12; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene
D: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bilateral Bispectral Index Monitoring During and After Electroconvulsive Therapy Compared With Magnetic Seizure Therapy for Treatment-resistant Depression
Brief Summary: Electroconvulsive therapy (ECT) has been shown to be an effective treatment for patients suffering from depression, who do not respond to medical treatment. However it is often dismissed by patients, who feel uncomfortably about the application of electric shocks to their heads. In 2000, magnetic seizure therapy (MST) has been introduced which uses magnetism instead of electricity to evoke convulsions. MST seems to be as effective as ECT in terms of its antidepressant potency but may be associated with less severe cognitive side effects.

Control of anaesthesia during seizure therapy is demanding since light anesthesia might be associated with awareness, whereas deep anesthesia impedes the antidepressant effect of the convulsion. Therefore, Bispectral index (BIS) monitoring is frequently used to tailor anaesthesia for ECT, however little is known about BIS following MST.

The investigators hypothesize that in comparing MST with ECT, (a) patients show a faster increase in BIS and that (b)less left-right differences occur in BIS.


Options:
A: Arm Label: Magnetic Seizure Therapy (MST); Type: EXPERIMENTAL; Interventions: Device: MagVenture MagPro MST | Arm Label: RUL ECT; Type: ACTIVE_COMPARATOR; Interventions: Biological: RUL ECT | Intervention Type: DEVICE; Name: MagVenture MagPro MST; Assigned to Arm(s): Magnetic Seizure Therapy (MST) | Intervention Type: BIOLOGICAL; Name: RUL ECT; Assigned to Arm(s): RUL ECT
B: Arm Label: Magnetic Seizure Therapy (MST); Type: EXPERIMENTAL; Interventions: Device: Tonica MagPro MST | Arm Label: Electroconvulsive Therapy (ECT); Type: ACTIVE_COMPARATOR; Interventions: Device: Thymatron | Intervention Type: DEVICE; Name: Thymatron; Assigned to Arm(s): Electroconvulsive Therapy (ECT) | Intervention Type: DEVICE; Name: Tonica MagPro MST; Assigned to Arm(s): Magnetic Seizure Therapy (MST)
C: Arm Label: Active Treatment; Type: EXPERIMENTAL; Interventions: Device: MST | Intervention Type: DEVICE; Name: MST; Assigned to Arm(s): Active Treatment
D: Arm Label: Magnetic Seizure Therapy Group; Type: N/A; Interventions: N/A | Arm Label: Electroconvulsive Therapy Group; Type: N/A; Interventions: N/A

Answer: D